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To evaluate both the intra and inter-reader reproducibility of Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) for scoring and measurement of intra-prostatic lesions at mpMRI.
Materials and Methods: 
In 102 consecutive biopsy-naïve patients who underwent prostate magnetic resonance imaging (MRI) at 3T using endorectal with phased array surface coil and subsequent MR/transrectal ultrasonography (MR/TRUS) guided biopsy, previously detected and biopsied lesions were scored by four readers from four different institutions using PI-RADSv2. MRI protocol included T2-weighted, diffusion-weighted (DW) and dynamic contrast enhanced (DCE) MRI. Readers scored lesions using PI-RADSv2 during two read out rounds with a four-week washout period. Kappa (κ) statistics and specific agreement (Po) were calculated to quantify intra and inter-reader reproducibility of PI-RADSv2 scoring. Lesion measurement agreement was calculated using Interclass Correlation Coefficient (ICC).
Results:
Overall intra-reader reproducibility was moderate to substantial (κ = 0.43 – 0.67, Po = 0.60 – 0.77), while overall inter-reader reproducibility was poor (κ = 0.24, Po = 46).  Readers with more experience showed greater inter-reader reproducibility than readers with intermediate experience in the whole prostate (p = 0.026) and peripheral zone (p = 0.002). Sequence specific inter-reader agreement for all readers was similar to overall PI-RADSv2 score, with κ=0.24, 0.24, and 0.23 and po=0.47, 0.44, and 0.54 in T2W, DWI, and DCE, respectively. Overall intra-reader and inter-reader ICC for lesion measurement was 0.82 and 0.71, respectively.
Conclusion:







Implications for Patient Care:
	This study can help prostate cancer providers better understand the variability that exists in prostate MRI interpretation, leading to more appropriate application of prostate MRI findings.
	Efforts should be directed at minimizing differences in interpretation practices, which would enable those interpreting prostate MRI to produce more uniform results, improving confidence in the results.

Summary Statement:







The role of magnetic resonance imaging (MRI) of prostate cancer has expanded within the last decade, and now includes tumor detection and characterization, risk stratification, image guidance for biopsy and focal therapy and local staging and treatment planning for radiation therapy  ADDIN EN.CITE (1-3).  As prostate multiparametric magnetic resonance imaging (mpMRI) has become increasingly utilized, the need for a universal and standardized system for reporting findings has become even more apparent. Addressing this issue, the European Society of Urogenital Radiology (ESUR) introduced the first structured reporting system: the prostate imaging reporting and data system (PI-RADS), which was modeled on the BI-RADS system designed for breast cancer  ADDIN EN.CITE (4, 5). Following its initial implementation, PI-RADS was found to have an overly complicated scoring system with wide ranging inter-reader reproducibility  ADDIN EN.CITE (2, 6-9). Following the recommendations of an international working group,  PI-RADS version 2 (PI-RADS v2) emerged, aiming to simplify the scoring system and  standardize the nomenclature (3). 
While PI-RADSv2 has simplified scoring by changing to a 5-point scale, there remain many concerns about its inter-reader reproducibility, with studies showing found poor to moderate agreement (10-12). Results are often dependent on reader experience level and lesion location within the prostate, with a higher inter-reader reproducibility among lesions in the posterior peripheral zone (PZ) than in the transition zone (TZ) (10). It is important for any scoring system that it have high intra- and inter-reader reproducibility and, while inter-reader reproducibility has been studied, there has been a paucity of studies investigating the intra-reader reproducibility of PI-RADSv2. 
The purpose of this study was to investigate the intra and inter-reader reproducibility of PI-RADSv2 and provide further insight into the current landscape of the PI-RADSv2 reader agreement now, several years, into its implementation. 

Methods
Study Design and Patient Population
This retrospective study was compliant with the Health Insurance Portability and Accountability Act and was approved by the local ethics committee. Written informed consent was obtained from all patients. One hundred and two consecutive biopsy-naïve patients (median age 64 [44-84]; median PSA 5.95 ng/ml [1.17-113.6]) who underwent mpMR imaging between May 2015 and May 2017 and subsequently underwent MRI/transrectal ultrasound (TRUS) fusion-guided biopsy of lesions suspected to be cancer were included in the study. Exclusion criteria were having undergone previous prostate biopsy or non-diagnostic multiparametric MRI or not undergoing fusion biopsy.
MR Imaging Protocol
All imaging studies were performed with a combination of an endorectal coil (BPX-15; Medrad, Pittsburgh, Pa) tuned to 127.8 MHz and a six-channel cardiac coil with a parallel imaging (sensitivity-encoding [SENSE]; Philips Medical Systems, Best, the Netherlands) technique with a 3-T MR imager (Achieva; Philips Medical Systems). The endorectal coil was filled with 45 mL of Galden Perfluorinated Fluid (Solvay Specialty Polymers, Milan, Italy). MR imaging parameters included T1-weighted imaging, triplanar (coronal, sagittal, and axial) T2-weighted (T2W) turbo-spin-echo, DWI, apparent diffusion coefficient maps, high b-value DWI (b2000 sec/mm2) and DCE MRI sequences. Axial DCE images were obtained before, during, and after a single dose of gadopentetate dimeglumine (Magnevist; Berlex, Wayne, NJ) or more recently  gadoterate meglumine (Dotarem, Guerbet, Bloomington, IN) administered at a dose of 0.1 mmol/kg of body weight through a peripheral vein at a rate of 3 mL/sec by using a mechanical injector (Spectris MR Injection System; Medrad, Pittsburgh, Pa). MR imaging pulse sequence parameters are defined in Supplementary Table 1.
Reference Standard
Lesions suspicious for cancer on mpMRI were prospectively detected by an in-house expert prostate radiologist (10 years of experience with approximately 6,500 examinations) per standard clinical protocol. Using an office-based fusion platform (UroNav; InVivo Corp, Gainesville, Fla), either one highly experienced urologist or interventional radiologist (both of whom had performed >1500 MRI/TRUS fusion guided biopsies at the time of the study) performed MRI/TRUS fusion-guided biopsies on patients with one or more lesions suspicious for prostate cancer on mpMRI  ADDIN EN.CITE (13). All mpMRI-defined target lesions were sampled in the axial and sagittal plane, which resulted in two cores per target (14). 
Repeat PI-RADSv2 Scoring Procedure 
Four readers from different institutions with varying levels of experience reading mpMRI of the prostate were included in this study (reader 1, H.S., with 6 years of experience [approximately 1,500 examinations]; reader 2, Y.M.L. with 5 years of experience [approximately 1,500 examinations]; reader 3, T.B., with 7 years of experience [approximately 2,500 examinations]; reader 4, L.B. with 10 years of experience [approximately 8,500 examinations]). Readers were provided full mpMR imaging and screenshots of locations (Supplementary Figure 1) for all lesions sampled by MRI/TRUS guided biopsy sessions. For each target lesion, readers followed PI-RADSv2 guidelines for scoring each pulse sequence (e.g. T2W, DWI and DCE), longest axial dimension, and an overall PI-RADSv2 score (3). Readers were also asked to report the pulse sequence they used to make the measurement. This evaluation process was repeated after a four-week washout period following a re-randomization in the patient MR data to avoid any possible recalls from the first session.
Statistical Analysis
Scoring agreement was examined both within (intra-reader) and across (inter-reader) readers for all reported PI-RADSv2 scoring (Overall, T2W, DWI, and DCE) and lesion size. Scoring agreement was calculated using two methods, kappa statistic and specific agreement (15). Specific agreement describes the overall proportion of observed agreement (po) across all scoring categories, defined as the sum of category-wise agreements relative to the total number of category-wise opportunities for agreement. Cohen’s kappa was applied in the case of pairwise reader comparison (intra-reader or paired inter-reader stratified by experience) and Fleiss’ kappa was applied in the case of four-reader comparison (overall inter-reader agreement).
Lesion size agreement was assessed using Intraclass Correlation Coefficient (ICC), estimated from a mixed effects model of log-transformed size measurements considering nested random effects from patient, lesions, and readers and fixed effect from reader experience. Variables contributing to variance in lesion size were estimated by the likelihood ratio test. Limits of agreement (LOA) for lesion size measurements were estimated from the sum of the variance components of final mixed effect model. Coverage probability (CP) was calculated as the percent of lesions contained within varying limits of size measurement agreement, assessed for each reader as the absolute difference in lesion size between round 1 and round 2 measurements.
Standard errors and 95% Confidence Intervals (CI) were estimated from 2000 bootstrap samples by random sampling on the patient-level to account for intra-lesion correlation. The Wald test was used to test the difference in inter-reader agreement for moderate vs. experienced readers. All p-values correspond to two-sided tests, with a p-value <0.05 considered to represent a significant difference.

Results
Patient and Lesion Characteristics
Table 1 shows baseline characteristics of our study population. 121/205 lesions were benign and 55/205 were clinically significant cancers (GS ≥ 3+4 = 7). The majority of lesions were located in the PZ (N=155), with fewer lesions in the TZ (N=49) and one lesion in the central zone (CZ).
Lesion Scoring Distribution
Considering the distribution of PI-RADSv2 scores in both rounds, category 5 showed highest prevalence of agreement and category 3 showed lowest prevalence of agreement (Figure 1A). For lesions scored category 5 by any reader, there was consensus by majority (3+) readers in 34% (12/35) in round 1 and 39% (12/31) in round 2. A similar pattern of majority consensus was observed in category 4 lesions read by any reader, 32% (47/145) in round 1 and 34% (46/137) in round 2. In category 2lesions, a consensus by majority was reached in 23% (34/148) and 30% (44/148) for the first and second round. Agreement by majority of readers was lowest in PI-RADSv2 category 3 at 9% (9/102) and 8% (8/102) for rounds 1 and 2, respectively. Representative lesions with high scoring agreement and low scoring agreement are shown in Figures 1B and 1C, respectively.  
Intra-Reader Reproducibility
Intra-reader kappa (κ) and specific agreement (po) reproducibility estimates for PI-RADSv2 overall score assignment are listed for all readers and all zones in Table 2. Overall, intra-reader reproducibility by kappa was moderate to high in all readers (κ=0.43-0.67), with average specific agreement 70% across all readers (po range 0.60-0.74) reflecting the overall proportion of lesions with concordant scoring. Expert readers demonstrated higher intra-reader agreement (κ=0.62-0.66; po=0.76-0.79) compared to moderate readers (κ=0.39-0.49; po=0.60-0.69) in PZ lesions. This trend was not observed in TZ lesions. 
Intra-reader reproducibility of PI-RADSv2 pulse sequence scoring (T2W, DWI, DCE) in all lesions are shown in Figure 2. Comparing to PI-RADSv2 overall scores, intra-reader reproducibility was lower in sequence specific scoring for a majority of readers. Expert readers demonstrated higher intra-reader reproducibility (κ=0.53-0.65; po=0.67-0.73) compared to moderate readers (κ=0.33-0.44; po=0.56-62) in DWI. No differences in intra-reader reproducibility across reader experience were observed for T2W and DCE scoring. Zone-specific assessment of intra-reader reproducibility for all sequences is reported in Supplementary Table 2. 
Inter-Reader Reproducibility
	Inter-reader agreement for all readers was poor (κ=0.24) with specific agreement occurring in only 46% as summarized in Table 3. Pairwise agreement between moderate and expert readers demonstrated superior scoring agreement between expert readers, with better agreement for PZ lesions (κ=0.23 and 0.43 in moderates and experts, respectively, p=0.002) and specific agreement (po=0.51 and 0.62 in moderates and experts, respectively, p=0.009). No significant differences in pairwise inter-reader agreement stratified by reader experience was observed in TZ lesions (Table 3). 
	Figure 3 shows inter-reader agreement by pulse sequence (T2W, DWI, and DCE) for all readers with pairwise stratification by reader experience. Sequence specific inter-reader agreement for all readers was similar to the results for overall score (κ=0.24, 0.24, and 0.23 and po=0.47, 0.44, and 0.54 in T2W, DWI, and DCE, respectively). Expert readers demonstrated higher agreement in DWI scoring using both similarity metrics (Figure 3). In T2W, the observed proportion of agreement was 45% in moderate readers vs 58% in expert readers (p=0.0002), while kappa showed a trend favoring expert readers (κ=0.25 vs 0.35, p=0.077). No differences in DCE scoring were observed among all readers or by pairwise agreement stratified by reader experience. Zone-specific sequence based inter-reader reproducibility for all readers, expert readers, and moderate readers is reported in Supplementary Table 3. 
Lesion Measurement Agreement
Overall intra-reader ICC was 0.82, with similar performance across both prostatic zones (Table 4). Agreement in lesion size for all readers was more moderate, with overall inter-reader ICC 0.71 influenced by a relatively poorer agreement in TZ (ICC=0.58). Reader experience was found to significantly contribute to lesion size variability in the mixed effect model (Χ2=70.5, p<0.0001). Variance estimates derived from mixed effects model demonstrate lesion size differences up to +/-4.8mm on two measurements are within statistical limits (LOA) of expected variability across all readers for all lesions. The proportion of lesions falling (CP) within 1mm incremental limits of lesion size difference are shown in Figure 4. Despite the average of all readers achieving 95% CP at +/-5mm limit, reader-specific 95% CP is achieved at variable limits (range 3-6mm). Reader 2 (expert) showed the highest reproducibility in lesion size measurements, nearing 95% CP at 2mm. 

Discussion
Our study suggests that PI-RADSv2 has overall moderate to good intra-reader reproducibility and poor to moderate inter-reader reproducibility and lesion measurement agreement. Our overall intra-reader reproducibility findings show moderate to good agreement, with experts having overall higher intra-reader reproducibility than moderate experience level readers. Reproducibility was lower in T2W and DWI sequences than overall scoring, except for reader 1. Overall, our study shows similar scoring reproducibility compared to BI-RADS literature, which reports moderate to good intra-reader reproducibility ranging from κ=0.53-0.77  ADDIN EN.CITE (16-18).  As indicated in other reader agreement studies, alternative statistical metrics can be utilized to inform raw agreement in addition to the traditional kappa statistic due to the variability of kappa by the presence and distribution of scoring observations  ADDIN EN.CITE (6, 15, 19). In this study, we report the overall proportion of specific agreement for intra-reader reproducibility in PI-RADSv2 overall scoring to be 60-77% across all readers, with a higher proportion of lesion-based scoring agreement in expert readers compared to moderate readers. The intra-reader reproducibility has implications for within-institution lesion interpretation and reporting. It is important for prostate MRI centers to carry-out in-house investigations of their readers’ own reproducibility. Furthermore, the moderate intra-reader reproducibility observed in this study indicates that variability in individual reader performance influences agreement in multi-reader studies. 
Inter-reader reproducibility was poor to moderate in our study, which aligns with the current PI-RADSv2 inter-reader literature. Sonn et al. (12) had 9 single center radiologists prospectively evaluate prostate mpMRIs and found “considerable variability in PIRADS score assignment.” Both Muller et al. (10) and Rosenkrantz et al. (11) found only moderate reproducibility among beginner to moderately experienced readers while expert readers had only slightly better performance. In our study, the greatest consensus among readers was reached for category 4 and 5 lesions, and poor consensus was reached for category 3 lesions. This supports current PI-RADS reader agreement literature, which shows greatest agreement among higher PI-RADSv2 categories  ADDIN EN.CITE (11, 20). We additionally report differences in reader agreement across prostate zones. Experts show highest agreement in the PZ using the DWI sequence (κ= 0.49, po= 0.56). Although still only moderate in reproducibility, it is reassuring that the best agreement occurs for the dominant sequence used in the zone where most cancerous lesions exist (21). The TZ also contains the majority of BPH disease, which can appear similar to cancer, influencing interpretation of this zone. This could contribute to the considerable number of lesions with equal proportion of PI-RADSv2 category 2 and 4 assignments across readers in both rounds (Figure 1A).  
Lesion size agreement was moderate across all readers (ICC=0.71), leading to overall limits of agreement of +/-4.8mm to capture approximately 95% of measurements. The poor reproducibility observed in this study, resulting in wide confidence intervals, is important to consider in longitudinal assessment of prostate lesions on mpMRI. Recent work in the use of mpMRI for patients on active surveillance have suggested 2-3mm increases can represent meaningful progression  ADDIN EN.CITE (22-24). Only one of four readers achieved accuracy within this range, with others ranging from 4-6mm to achieve 95% coverage by which statistical inference on changes in lesion size can be made. The results of this study should further be evaluated in an active surveillance population and in the context of true disease progression.
The imperfect agreement of PI-RADSv2 readings is likely due to many factors. First, there is a high degree of signal pattern complexity within the prostate on mpMRI. Despite working with PI-RADSv2 since 2015, readers of all experience levels continue to have difficulty agreeing with each other on category assignment, especially, category 3 (10). Readers have also shown poor agreement when attempting to draw the tumor location on a PI-RADSv2 sector map, which raises concerns about accurate tumor localization (25). In addition, readers have difficulty in the interpretation and application of the PI-RADSv2 lexicon, as expert readers only show moderate agreement when using it (11). It is also possible that the multiple manifestations of cancer on mpMRI are poorly encompassed by PI-RADSv2 and its lexicon, leading to confusion and poor agreement. Finally, readers may have distinctive styles in their application of PI-RADS. For example, one reader may attempt to strictly utilize the lexicon to score lesions while another reader may score lesions based on how the score will affect clinical outcomes. We believe that these factors, and possibly others, could be influencing reader decisions, reducing agreement by creating variability in intra-reader assessment which influences inter-reader agreement and clinical mpMRI utilization. 
Our study has several limitations. First, we selected lesions a priori for the readers to score as it allowed us to compare agreement of specific lesions. Because we needed to have biopsy validation of lesions, we could only use lesions that were deemed suspicious enough for biopsy. This likely selected for a more suspicious population of lesions than those presented in the every-day clinical setting. Despite this, most lesions were benign (121/205). However, we believe that our population reflects real life referrals considering more wide use of prostate MRI for biopsy guidance rather than staging in surgery populations. This dichotomous cohort of suspicious yet benign lesions may have been misleading to readers, causing some disagreement. Despite this, a strength of this study is its relatively large biopsy-naïve, consecutive patient cohort.



























	Note.- Median values with ranges reported in parentheses. PSA = prostate-specific




































 	PI-RADSv2 Overall Scoring: Intra-Reader Repeatability by Prostate Zone Between Two Scoring Rounds	 
	Prostate Zone	Kappa Value [κ]	Specific Agreement [po]	
	Whole Prostate	 	 	
	Reader 1M	0.43 (0.32-0.54)	0.60 (0.53-0.67)	
	Reader 2M	0.54 (0.42-0.65)	0.70 (0.63-0.77)	
	Reader 3E	0.67 (0.59-0.75)	0.77 (0.71-0.83)	
	Reader 4E	0.55 (0.45-0.63)	0.74 (0.69-0.79)	
	Peripheral Zone	 	 	
	Reader 1M	0.39 (0.27-0.52)	0.60 (0.53-0.67)	
	Reader 2M	0.49 (0.35-0.62)	0.69 (0.61-0.77)	
	Reader 3E	0.66 (0.57-0.75)	0.76 (0.70-0.82)	
	Reader 4E	0.62 (0.52-0.71)	0.79 (0.73-0.84)	
	Transition Zone	 	 	
	Reader 1M	0.47 (0.27-0.65)	0.61 (0.47-0.75)	
	Reader 2M	0.57 (0.37-0.74)	0.71 (0.58-0.83)	
	Reader 3E	0.69 (0.49-0.86)	0.82 (0.69-0.92)	
	Reader 4E	0.32 (0.10-0.53)	0.59 (0.45-0.73)	






























 	PI-RADSv2 Overall Scoring: Inter-Reader Reproducibility by Zone	 
	Prostate Zone	Kappa Value (κ)	P Value	Specific Agreement (po)	P Value	 
	Whole Prostate	 	 	 	 	 
	All Readers	0.24 (0.18-0.30)	 	0.46 (0.43-0.50)	 	 
	Moderate Readers	0.27 (0.19-0.36)	0.026	0.51 (0.45-0.56)	0.007	 
	Expert Readers	0.40 (0.32-0.48)		0.61 (0.55-0.66)		 
	Peripheral Zone	 	 	 	 	 
	All Readers	0.23 (0.16-0.30)	 	0.46 (0.42-0.51)	 	 
	Moderate Readers	0.23 (0.12-0.34)	0.002	0.51 (0.45-0.58)	0.009	 
	Expert Readers	0.43 (0.34-0.53)		0.62 (0.56-0.68)		 
	Transition Zone	 	 	 	 	 
	All Readers	0.19 (0.10-0.28)	 	0.47 (0.40-0.53)	 	 
	Moderate Readers	0.27 (0.14-0.40)	0.929	0.49 (0.39-0.59)	0.347	 
	Expert Readers	0.26 (0.06-0.43)		0.56 (0.47-0.66)		 


































 	Lesion Size Interclass Correlation	 
 	Prostate Zone	ICC	 
 	Intra-Reader	 	 
 	WP	0.82 (0.78 - 0.86)	 
 	PZ	0.83 (0.77 - 0.87)	 
 	TZ	0.80 (0.72 - 0.86)	 
 	Inter-Reader	 	 
 	WP	0.71 (0.66 - 0.76)	 
 	PZ	0.74 (0.67 - 0.80)	 
 	TZ	0.58 (0.45 - 0.68)	 
































































































 	Multiparametric MR Imaging Sequence Parameters at 3T	 
 	Parameter	T2 Weighted	DWIa	High b-Value DWIb	DCE MR Imagingc	 
 	Field of view (mm)	140 × 140	140 × 140	140 × 140	262 × 262	 




 	Section thickness (mm), no gaps	3	3	3	3	 
 	Image reconstruction matrix (pixels)	512 × 512	256 × 256	256 × 256	256 × 256	 
 	Reconstruction voxel imaging
resolution (mm/pixel)	0.27 × 0.27 ×
3.00	0.55 × 0.55 ×
2.73	0.55 × 0.55 ×
2.73	1.02 × 1.02 ×
3.00	 
 	Tme for acquisition (min:sec)	2:48	4:54	3:50	5:16	 
 	aFor ADC map calculation. Five evenly-spaced b values (0-750 sec/mm2) were used.	 	 
 	bb= 2000 sec/mm2	 	 	 	 	 







 	Intra-Reader Repeatability by Pulse Sequence and Zone	 
 	 	 	Kappa Value (κ) (95% CI)	 	 	 	Specific Agreement (po) (95% CI)	 	 
 	 	All Zones	PZ	TZ	 	All Zones	PZ	TZ	 
 	T2W	 	 	 	 	 	 	 	 
 	Reader 1M	0.29 (0.21-0.41)	0.27 (0.17-0.39)	0.33 (0.15-0.55)		0.51 (0.44-0.58)	0.49 (0.41-0.56)	0.55 (0.42-0.69)	 
 	Reader 2M	0.53 (0.42-0.64)	0.53 (0.40-0.65)	0.45 (0.25-0.64)	 	0.67 (0.59-0.74)	0.67 (0.59-0.76)	0.65 (0.51-0.79)	 
 	Reader 3E	0.56 (0.46-0.65)	0.52 (0.41-0.63)	0.66 (0.47-0.83)		0.71 (0.64-0.78)	0.68 (0.60-0.75)	0.80 (0.67-0.90)	 
 	Reader 4E	0.49 (0.38-0.60)	0.56 (0.43-0.68)	0.26 (0.05-0.52)	 	0.72 (0.65-0.78)	0.75 (0.68-0.83)	0.59 (0.44-.74)	 
 	DWI								 
 	Reader 1M	0.44 (0.33-0.53)	0.43 (0.32-0.55)	0.47 (0.24-0.67)	 	0.62 (0.56-0.68)	0.63 (0.55-0.70)	0.61 (0.47-.75)	 
 	Reader 2M	0.33 (0.22-0.44)	0.36 (0.23-0.49)	0.21 (0.02-0.40)		0.56 (0.49-0.63)	0.59 (0.51-0.67)	0.45 (0.32-0.58)	 
 	Reader 3E	0.65 (0.57-0.73)	0.7 (0.61-0.79)	0.48 (0.27-0.68)	 	0.73 (0.67-0.79)	0.77 (0.71-0.84)	0.59 (0.45-0.73)	 
 	Reader 4E	0.53 (0.43-0.62)	0.56 (0.44-0.67)	0.42 (0.23-0.60)		0.67 (0.60-0.74)	0.71 (0.64-0.78)	0.55 (0.40-0.70)	 
 	DCE	 	 	 	 	 	 	 	 
 	Reader 1M	0.50 (0.37-0.61)	0.46 (0.32-0.60)	0.70 (0.34-0.93)		0.60 (0.52-0.67)	0.55 (0.46-0.63)	0.76 (0.63-0.88)	 
 	Reader 2M	0.51 (0.36-0.65)	0.49 (0.32-0.65)	0.57 (0.27-0.84)	 	0.56 (0.46-0.65)	0.54 (0.43-0.64)	0.61 (0.46-0.76)	 
 	Reader 3E	0.52 (0.41-0.63)	0.52 (0.39-0.65)	0.50 (0.24-0.73)		0.45 (0.38-0.53)	0.44 (0.35-0.53)	0.49 (0.34-0.63)	 
 	Reader 4E	0.53 (0.34-0.69)	0.54 (0.32-0.72)	0.45 (-0.04-0.85)	 	0.78 (0.71-0.85)	0.76 (0.69-0.83)	0.84 (0.71-0.94)	 











 	Inter-Reader Reproducibility by Pulse Sequence and Zone	 
 	 	 	Kappa Value (κ) (95% CI)	 	 	 	Specific Agreement (po) (95% CI)	 	 
 	 	All Zones	PZ	TZ	 	All Zones	PZ	TZ	 
 	T2W	 	 	 	 	 	 	 	 
 	All Readers	0.24 (0.17-0.30)	0.25 (0.18-0.33)	0.16 (0.06-0.24)		0.47 (0.44-0.51)	0.48 (0.43-0.52)	0.47 (0.41-0.53)	 
 	Moderate Readers	0.25 (0.16-0.33)	0.26 (0.16-0.35)	0.16 (0.04-0.29)	 	0.45 (0.39-0.51)	0.46 (0.39-0.53)	0.44 (0.33-0.54)	 
 	Expert Readers	0.34 (0.24-0.42)	0.37 (0.27-0.46)	0.21 (0.01-0.39)		0.58 (0.53-0.64)	0.59 (0.53-0.66)	0.54 (0.43-0.65)	 
 	DWI	 	 	 	 	 	 	 	 
 	All Readers	0.24 (0.18-0.29)	0.26 (0.18-0.33)	0.17 (0.08-0.25)		0.44 (0.40-0.48)	0.46 (0.41-0.51)	0.38 (0.32-0.44)	 
 	Moderate Readers	0.26 (0.19-0.34)	0.26 (0.16-0.36)	0.26 (0.12-0.38)	 	0.49 (0.43-0.54)	0.49 (0.43-0.56)	0.46 (0.36-0.56)	 
 	Expert Readers	0.43 (0.36-0.51)	0.49 (0.40-0.58)	0.28 (0.13-0.42)		0.58 (0.53-0.64)	0.63 (0.57-0.69)	0.44 (0.34-0.54)	 
 	DCE	 	 	 	 	 	 	 	 
 	All Readers	0.23 (0.16-0.30)	0.22 (0.15-0.30)	0.25 (0.09-0.41)		0.54 (0.47-0.60)	0.51 (0.44-0.58)	0.62 (0.50-0.73)	 
 	Moderate Readers	0.26 (0.12-0.39)	0.22 (0.06-0.38)	0.40 (0.10-0.64)	 	0.52 (0.45-0.60)	0.49 (0.41-0.58)	0.64 (0.51-0.78)	 
 	Expert Readers	0.16 (0.07-0.25)	0.15 (0.05-0.26)	0.16 (-0.02-0.36)		0.52 (0.45-0.59)	0.50 (0.42-0.58)	0.58 (0.45-0.69)	 
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